

Supplementary Table S3. Comparison according to chemotherapy regimens

Variable	S-1 (n= 199)	XELOX (n= 133)	P-value
Age (yr)	60.2 ± 12.4	54.4 ± 10.5	0.015 ^{a)}
Sex			0.836
Male	134 (67.3)	91 (68.4)	
Female	65 (32.7)	42 (31.6)	
BMI (kg/m ²)	23.4 ± 3.1	23.2 ± 3.6	0.463
ECOG			0.001 ^{a)}
0	138 (69.3)	120 (90.2)	
≥ 1	61 (30.7)	13 (9.8)	
CCI			0.046 ^{a)}
0	139 (69.8)	106 (79.7)	
≥ 1	60 (30.2)	27 (20.3)	
Pathologic stage			0.001 ^{a)}
II	128 (64.3)	23 (17.3)	
III	71 (35.7)	110 (82.7)	
CDC			0.612
≤ 2	41 (70.7)	25 (65.8)	
≥ 3	17 (29.3)	13 (34.2)	
Postoperative hospital stay (day)	8.8 ± 3.2	9.5 ± 4.0	0.014 ^{a)}
Interval from operation to chemotherapy (day)	36.3 ± 10.6	37.7 ± 10.3	0.250
Dose reduction			0.004 ^{a)}
Yes	11 (5.5)	20 (15.0)	
No	188 (94.5)	113 (85.0)	

Values are presented as mean ± standard deviation or number (%).

BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CCI, Charlson comorbidity index; CDC, Clavien-Dindo classification; S-1, tegafur/gimeracil/oteracil; XELOX, capecitabine plus oxaliplatin.

^{a)}Statistically significant, P < 0.05.